ustekinumab-ttwe 130 MG per 26 ML Injection

RxCUI: 2705557
RxNorm name: ustekinumab-ttwe 130 MG per 26 ML Injection
Display name: ustekinumab-ttwe 130 MG per 26 ML Injection
Full name: ustekinumab-ttwe 130 MG per 26 ML Injection
Term type: SY
Status: DailyMed mapping
Updated: 2026-06-04 23:39:26

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
761373	Pyzchiva	ustekinumab-ttwe	351(k) Interchangeable	Rx	2026-07-01
761425	Pyzchiva	ustekinumab-ttwe	351(k) Interchangeable	Rx	2026-07-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
PYZCHIVA	USTEKINUMAB-TTWE	SANDOZ INC	e8a14922-7902-4d9f-8ba5-d91dccffed29	2026-07-09	Warnings, Adverse reactions	Exact identifier rxcui: 2705557
USTEKINUMAB-TTWE	USTEKINUMAB-TTWE	Quallent Pharmaceuticals Health LLC	2b34392a-ecf6-41bd-8706-d4e9f0b25da8	2026-01-12	Warnings, Adverse reactions	Exact identifier rxcui: 2705557

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 2 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
e8a14922-7902-4d9f-8ba5-d91dccffed29	ustekinumab-ttwe 130 MG in 26 ML Injection [PSN] · 26 ML ustekinumab-ttwe 5 MG/ML Injection [SCD] · ustekinumab-ttwe 130 MG per 26 ML Injection [SY]	3	16	These highlights do not include all the information needed to use PYZCHIVA safely and effectively. See full prescribing information for PYZCHIVA. PYZCHIVA ® (ustekinumab-ttwe) injection, for subcutaneous or intravenous use Initial U.S. Approval: 2024 PYZCHIVA (ustekinumab-ttwe) is biosimilar* to STELARA (ustekinumab).	20260313
2b34392a-ecf6-41bd-8706-d4e9f0b25da8	ustekinumab-ttwe 130 MG in 26 ML Injection [PSN] · 26 ML ustekinumab-ttwe 5 MG/ML Injection [SCD] · ustekinumab-ttwe 130 MG per 26 ML Injection [SY]	3	6	These highlights do not include all the information needed to use USTEKINUMAB-TTWE safely and effectively. See full prescribing information for USTEKINUMAB-TTWE. USTEKINUMAB-TTWE injection, for subcutaneous or intravenous use Initial U.S. Approval: 2024 Ustekinumab-ttwe is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful dif	20260112